Core Insights - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery [1][3] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] - Septerna's proprietary Native Complex Platform™ is aimed at advancing GPCR therapies for patients with significant unmet medical needs [3] Company Overview - Septerna is developing a diverse pipeline of novel oral small molecule drug candidates targeting various therapeutic areas including endocrinology, immunology, inflammation, and metabolic diseases [3] - The company is led by a team of GPCR experts and drug developers [3] - Septerna collaborates with partners to enhance its drug discovery efforts [3] Presentation Details - Jeffrey Finer, M.D., Ph.D., CEO and co-founder of Septerna, will present at the conference [1] - A live webcast of the presentation will be available on the company's website and archived for at least 30 days [2]
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference